‘120 pages of data’: Roche’s pipeline review leads to asset cuts, but also additions
Roche disclosed on Wednesday it had cut several early- to mid-stage candidates after a broader R&D review, which also saw pipeline additions and triggered recently-announced acquisitions and partnerships.
During the company’s pipeline evaluation, dubbed the R&D Excellence initiative, its researchers were clear on what the most promising molecules are based on “120 pages of data,” CEO Thomas Schinecker said during a media call, adding that it had made decisions in the third quarter of last year. “So, what’s the dead horse that we are riding that we should stop… if you do everything at the same speed, you’re not going to be fast,” he added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.